Blood test could personalize chemo breaks for advanced colon cancer
NCT ID NCT06446557
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether a blood test that measures tumor DNA (ctDNA) can help doctors decide when to reduce or switch chemotherapy in people with metastatic colorectal cancer. About 408 participants will be randomly assigned to either standard treatment or a strategy where ctDNA levels guide whether they stop chemo, continue with a milder maintenance, or switch drugs. The goal is to see if the ctDNA-guided approach improves survival while maintaining quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- chemotherapy plus targeted agent (anti-EGFR or bevacizumab)
- What this could lead to
- If successful, this could show that using a simple blood test to guide treatment decisions improves survival and quality of life for people with metastatic colorectal cancer.
- What could go wrong
- This is a large phase 3 trial, but it only includes a specific subset of patients (left-sided, MSS, BRAF wild-type). The ctDNA test may not work as expected, and the experimental strategy could be no better or even worse than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLON CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de ROUEN
Rouen, 76031, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Two-Drug combo outsmart resistant colorectal cancer?
- Could a personal coach at home boost energy for cancer patients?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?